Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101996 | 0.83 | SMN1; SMN2 (0.53) | CA1CA2SMN1; SMN2LMNAHTT | |
| SCHEMBL4098746 | 0.80 | SMN1; SMN2 (0.56) | CA1CA2SMN1; SMN2HTTCA9 | |
| SCHEMBL13667976 | 0.79 | SMN1; SMN2 (0.57) | CA1CA2SMN1; SMN2LMNAHTT | |
| SCHEMBL2891113 | 0.79 | CA1 (0.66) | CA1CA2LMNACA9ALDH1A1 | |
| SCHEMBL483832 | 0.78 | CA1 (0.70) | CA1CA2LMNAGAACA9 | |
| SCHEMBL5128303 | 0.77 | MAPT (0.61) | CA1CA2LMNAHTTGAA | |
| SCHEMBL7629070 | 0.77 | SMN1; SMN2 (0.80) | CA1CA2SMN1; SMN2LMNAHTT | |
| SCHEMBL7205247 | 0.76 | CA1 (0.49) | CA1CA2SMN1; SMN2HTTCA9 | |
| SCHEMBL668791 | 0.75 | CA1 (0.66) | CA1CA2SMN1; SMN2LMNACA9 | |
| SCHEMBL1476527 | 0.75 | CA2 (1.00) | CA1CA2LMNAHTTCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| US-7317031-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317031-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317031-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1712550-A2 | Substituted triazole diamine derivatives as kinase inhibitors | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050182116-A1 | Substituted triazole diamine derivatives as kinase inhibitors | LIN RONGHUI (US) | 2005-08-18 | — | — | US | disclosed |
| US-6924302-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040077699-A1 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1355889-A1 | SUBSTITUTED TRIAZOLE DIAMINE DERIVATIVES AS KINASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| WO-2002057240-A1 | SUBSTITUTED TRIAZOLE DIAMINE DERIVATIVES AS KINASE INHIBITORS | ORTHO MC NEIL PHARMACEUTICAL, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | CA1 4782/4885CA2 2160/4885SMN1; SMN2 4405/4885 |
| US-20050182116-A1 | Substituted triazole diamine derivatives as kinase inhibitors | MAP2K2, PRKDC, MAP2K3 | CA1 4125/4885CA2 3433/4885SMN1; SMN2 1638/4885 |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA1 4813/4885CA2 4793/4885SMN1; SMN2 2853/4885 |
| US-20040077699-A1 | Substituted triazole diamine derivatives as kinase inhibitors | MAP2K2, PRKDC, MAP2K3 | CA1 4125/4885CA2 3433/4885SMN1; SMN2 1638/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA1 4813/4885CA2 4793/4885SMN1; SMN2 2853/4885 |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | CA1 2635/4885CA2 2143/4885SMN1; SMN2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.